Collagen Hybridizing Peptides (CHPs) can monitor collagen degradation in multiple myeloma, crucial for understanding the disease's progression and response to treatment.
CHP staining intensity serves as a marker for the degree of collagen remodeling, which is a hallmark of fibrotic disease activity and progression
Multiple myeloma (MM) involves the uncontrolled proliferation of plasma cells in the bone marrow, often accompanied by bone marrow fibrosis, characterized by abnormal collagen deposition.
Explore the potential of targeted collagen analysis to improve understanding and treatment of Multiple Myeloma. Download our application flyer for details on how CHPs can advance your research.
CHPs enable the precise measurement of inflammation and tissue damage in a number of conditions.
Our CHP products are conjugated with a variety of detection motifs for brightfield and fluorescence detection, and they can be customized to meet your unique needs. Visit our products page to learn more.
Our experts are here to help.
Contact UsThanks for subscribing!
This email has been registered!